BioSpace News Archive

NeuroMetrix, Inc. reported financial and business highlights for the quarter ended June 30, 2021.

Landos Biopharma, Inc. announced that data from the Phase 2 clinical trial of omilancor in ulcerative colitis has been accepted for oral presentation at the upcoming United European Gastroenterology Week 2021.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT™-GBM clinical trial for recurrent glioblastoma has been successfully treated.

Cerevel Therapeutics today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2021 financial results and recent business and pipeline updates on Wednesday,

Global Blood Therapeutics, Inc. announced updates across several of its development programs in sickle cell disease.

Annexon to host virtual autoimmune R&D event with leading experts on Wednesday, July 28, at 10:30 a.m. ET

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.

Tectonic Therapeutic today announced that Dr. Marcella (“Marcie”) Ruddy, MD has been appointed Chief Medical Officer.

Seres Therapeutics, Inc. today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Glaukos Corporation announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held July 23–27, 2021 in Las Vegas, Nevada.